Literature DB >> 8702538

A single N-linked glycosylation site is implicated in the regulation of ligand recognition by the I-type lectins CD22 and CD33.

D Sgroi1, A Nocks, I Stamenkovic.   

Abstract

CD22 is an immunoglobulin superfamily B lymphocyte-specific adhesion receptor and a member of the recently identified I-type class of lectins. Recent work has shown that CD22 specifically recognizes sialic acid linked alpha2,6 to terminal N-linked oligosaccharides on selected cell surface glycoproteins. CD22-ligand interaction is regulated by the activity of a beta-galactoside alpha2, 6-sialyltransferase that can inactivate CD22-mediated binding by sialylating the CD22 receptor itself. These observations suggest that N-linked glycosylation sites on the CD22 molecule may play a role in the regulation of CD22-mediated adhesion. In this work we have performed site-specific mutagenesis of potential N-linked glycosylation sites on CD22 in an effort to determine whether they might be involved in ligand recognition. We show that mutation of a single potential N-linked glycosylation site in the first immunoglobulin domain of CD22 completely abrogates ligand recognition. Interestingly, this site is characterized by the sequence NCT, where the cysteine is thought to be involved in an intrachain disulfide bond. Site-directed mutagenesis of similar NC(T/S) motifs in the first or second Ig domains of the I-type lectins myelin-associated glycoprotein, and sialoadhesin did not disrupt their ability to mediate sialic acid binding. In contrast, mutation of a NCS motif in the first Ig domain of the I-type lectin CD33 unmasked its sialic acid binding activity. These observations suggest that a single N-linked glycosylation site located at a similar position in the CD22 and CD33 glycoproteins is critical for regulating ligand recognition by both receptors.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8702538     DOI: 10.1074/jbc.271.31.18803

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  11 in total

1.  Natural ligands for CD33-related Siglecs?

Authors:  Ajit Varki
Journal:  Glycobiology       Date:  2009-05-09       Impact factor: 4.313

Review 2.  The sialyl-alpha2,6-lactosaminyl-structure: biosynthesis and functional role.

Authors:  F Dall'Olio
Journal:  Glycoconj J       Date:  2000-10       Impact factor: 2.916

Review 3.  Viewing Siglecs through the lens of tumor immunology.

Authors:  Isabella Fraschilla; Shiv Pillai
Journal:  Immunol Rev       Date:  2017-03       Impact factor: 12.988

Review 4.  Structural biology of cell surface receptors implicated in Alzheimer's disease.

Authors:  Stefan J Hermans; Tracy L Nero; Craig J Morton; Jonathan H Gooi; Gabriela A N Crespi; Nancy C Hancock; Chen Gao; Kenta Ishii; Jasmina Markulić; Michael W Parker
Journal:  Biophys Rev       Date:  2021-11-18

5.  High allelic polymorphism, moderate sequence diversity and diversifying selection for B-NK but not B-lec, the pair of lectin-like receptor genes in the chicken MHC.

Authors:  Sally L Rogers; Jim Kaufman
Journal:  Immunogenetics       Date:  2008-06-24       Impact factor: 2.846

6.  Glycosylation of FcgammaRIII in N163 as mechanism of regulating receptor affinity.

Authors:  Bettina Drescher; Torsten Witte; Reinhold E Schmidt
Journal:  Immunology       Date:  2003-11       Impact factor: 7.397

7.  Masking and unmasking of the sialic acid-binding lectin activity of CD22 (Siglec-2) on B lymphocytes.

Authors:  N Razi; A Varki
Journal:  Proc Natl Acad Sci U S A       Date:  1998-06-23       Impact factor: 11.205

Review 8.  Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicin.

Authors:  Andrew J Cowan; George S Laszlo; Elihu H Estey; Roland B Walter
Journal:  Front Biosci (Landmark Ed)       Date:  2013-06-01

Review 9.  Molecular diversity and evolution of the Siglec family of cell-surface lectins.

Authors:  Takashi Angata
Journal:  Mol Divers       Date:  2006-11       Impact factor: 3.364

10.  Identification of a novel inducible cell-surface ligand of CD5 on activated lymphocytes.

Authors:  L Biancone; M A Bowen; A Lim; A Aruffo; G Andres; I Stamenkovic
Journal:  J Exp Med       Date:  1996-09-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.